menu
    • menu
    [{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"AchE","graph1":"Immunology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Alter Pharma"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Acetate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Woodward Pharma Services","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Woodward Pharma Services"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Acella Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Milla Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Milla Pharmaceuticals

    Menu

    Milla Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Acetate

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Woodward Pharma Services

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL

                            Details : Sodium Acetate-generic Injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.

                            Brand Name : Sodium Acetate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 09, 2024

                            Lead Product(s) : Sodium Acetate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Woodward Pharma Services

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Acella Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup

                            Details : Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.

                            Brand Name : Mestinon-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2023

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Acella Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another “First Cycle” FDA Approval for ...

                            Details : Dexmedetomidine hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.

                            Brand Name : Precedex-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2023

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Milla Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Alter Pharma group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Milla Pharmaceuticals Announces Third ANDA Approval and The 4th U.S. Approval for the Alter Pharma Group

                            Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.

                            Brand Name : Pyridostigmine Bromide-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Alter Pharma group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth